A Phase 2 Neoadjuvant Study to Evaluate the Effects of CUE-101 on the Tumor Microenvironment in Patients with Locally Advanced/Resectable Head and Neck Squamous Cell Carcinoma (HNSCC)
Latest Information Update: 16 May 2021
At a glance
- Drugs CUE 101 (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Cue Biopharma
- 10 May 2021 According to a Cue Biopharma media release, the company plans to initiate this Phase 2 study in the second half of 2021.
- 19 Jun 2020 New trial record
- 15 Jun 2020 According to a Cue Biopharma media release, the company expects to initiate this trial later this year.